Issued 2026-09-16 at $24.53 · now $24.53 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, VICI has typically landed between $22.43 and $26.69 — a range of −8.6% to +8.8% from the issuance price $24.53.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,219 overlapping 1 month windows · 2017-10-17 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($24.53) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where VICI has typically landed a month from the 2026-09-16 close of $24.53 — the range is history, not a prediction.
- now $24.53 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $24.47 (-0.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $23.61–$25.34
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $22.43–$26.69
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-18 | −59.8% | −59.8% | +1.0% |
| 2020-02-21 | −58.3% | −60.2% | +0.0% |
| 2020-02-19 | −58.2% | −59.3% | +2.4% |
| 3 best | |||
| 2020-05-14 | +50.2% | +0.0% | +51.3% |
| 2020-05-13 | +49.9% | +0.0% | +54.6% |
| 2020-03-18 | +46.4% | +0.0% | +56.2% |
2,219 overlapping windows · 2017-10-17 – 2026-09-16 · not cherry-picked
Fundamentals iCompany financials — revenue, earnings, margins — from the newest filings shown, each carried with its date.iAs-reported figures and standard ratios from FMP, as of 2026-07-25. Revenue, net income and free cash flow can toggle annual or quarterly; margin, ROE and debt-to-equity are shown by fiscal year. We report the figures and the trend — no target price and no over/under-valued call. More on /methodology.
Fair value — three views iIndependent reference estimates of worth (a cash-flow model, peer multiples, analyst targets), shown as separate views — not a single verdict.
iThree independent estimates of per-share value, each by a different method and each with its own assumptions: a discounted-cash-flow intrinsic value, a peer comparable (the median trailing P/E of 29 sector peers times this company's trailing EPS), and the analyst price-target consensus. They routinely disagree — that gap is the point. We show the three marks and the current price; we do not blend them into a single number or call the stock over- or under-valued. Marks as of the latest capture. More on /methodology.- DCF (intrinsic)$137.59
- Peer P/E × EPS · sector median 32.9× · n=29$95.99
- Analyst target · range $27.00–$34.00$31.00
- Current price · last close 2026-09-16$24.53
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
98 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Douglas Monica Howard | director | Award / grant | 154 | 47,780 | Form 4 |
| 2026-07-01 | Cantor Diana F | director | Award / grant | 490 | 66,634 | Form 4 |
| 2026-07-01 | ABRAHAMSON JAMES R | director | Award / grant | 933 | 173,098 | Form 4 |
| 2026-07-01 | Holland Elizabeth I | director | Award / grant | 252 | 66,324 | Form 4 |
| 2026-07-01 | MACNAB CRAIG | director | Award / grant | 500 | 82,164 | Form 4 |
| 2026-07-01 | Rumbolz Michael D | director | Award / grant | 327 | 78,647 | Form 4 |
| 2026-06-01 | Pitoniak Edward Baltazar | director | Gift | 20,000 | 1,291,210 | Form 4 |
| 2026-04-28 | Cantor Diana F | director | Award / grant | 7,546 | 66,144 | Form 4 |
| 2026-04-28 | ABRAHAMSON JAMES R | director | Award / grant | 7,546 | 172,165 | Form 4 |
| 2026-04-28 | Douglas Monica Howard | director | Award / grant | 7,546 | 47,626 | Form 4 |
| 2026-04-28 | Holland Elizabeth I | director | Award / grant | 7,546 | 66,072 | Form 4 |
| 2026-04-28 | MACNAB CRAIG | director | Award / grant | 7,546 | 81,664 | Form 4 |
| 2026-04-28 | Rumbolz Michael D | director | Award / grant | 7,546 | 78,320 | Form 4 |
| 2026-04-01 | Holland Elizabeth I | director | Award / grant | 247 | 58,526 | Form 4 |
| 2026-04-01 | ABRAHAMSON JAMES R | director | Award / grant | 914 | 164,619 | Form 4 |
| 2026-04-01 | MACNAB CRAIG | director | Award / grant | 412 | 74,118 | Form 4 |
| 2026-04-01 | Rumbolz Michael D | director | Award / grant | 320 | 70,774 | Form 4 |
| 2026-04-01 | Douglas Monica Howard | director | Award / grant | 151 | 40,080 | Form 4 |
| 2026-04-01 | Cantor Diana F | director | Award / grant | 480 | 58,598 | Form 4 |
| 2026-02-24 | Wasserman Gabriel | officer | Award / grant | 5,071 | 41,838 | Form 4 |
| 2026-02-24 | Payne John W R | officer | Award / grant | 31,724 | 474,365 | Form 4 |
| 2026-02-24 | Gallagher Samantha Sacks | officer | Award / grant | 30,309 | 368,018 | Form 4 |
| 2026-02-24 | Pitoniak Edward Baltazar | director | Award / grant | 105,068 | 1,311,210 | Form 4 |
| 2026-02-24 | KIESKE DAVID ANDREW | director | Award / grant | 38,150 | 417,500 | Form 4 |
| 2026-02-23 | Pitoniak Edward Baltazar | director | Withheld for tax | 26,901 | 1,206,142 | Form 4 |
| 2026-02-23 | KIESKE DAVID ANDREW | director | Withheld for tax | 6,797 | 379,350 | Form 4 |
| 2026-02-23 | Gallagher Samantha Sacks | officer | Withheld for tax | 4,671 | 337,709 | Form 4 |
| 2026-02-23 | Payne John W R | officer | Withheld for tax | 4,577 | 442,641 | Form 4 |
| 2026-02-23 | Wasserman Gabriel | officer | Withheld for tax | 1,105 | 36,767 | Form 4 |
| 2026-02-20 | Pitoniak Edward Baltazar | director | Withheld for tax | 10,640 | 1,233,043 | Form 4 |
| 2026-02-20 | KIESKE DAVID ANDREW | director | Withheld for tax | 4,488 | 386,147 | Form 4 |
| 2026-02-20 | Gallagher Samantha Sacks | officer | Withheld for tax | 3,554 | 342,380 | Form 4 |
| 2026-02-20 | Payne John W R | officer | Withheld for tax | 2,827 | 447,218 | Form 4 |
| 2026-02-20 | Wasserman Gabriel | officer | Withheld for tax | 625 | 37,872 | Form 4 |
| 2026-01-02 | ABRAHAMSON JAMES R | director | Award / grant | 893 | 165,318 | Form 4 |
| 2026-01-02 | MACNAB CRAIG | director | Award / grant | 402 | 73,706 | Form 4 |
| 2026-01-02 | Douglas Monica Howard | director | Award / grant | 148 | 39,929 | Form 4 |
| 2026-01-02 | Cantor Diana F | director | Award / grant | 469 | 58,118 | Form 4 |
| 2026-01-02 | Holland Elizabeth I | director | Award / grant | 241 | 58,279 | Form 4 |
| 2026-01-02 | Rumbolz Michael D | director | Award / grant | 313 | 70,454 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures iStock trades disclosed by members of Congress for this company, by the date they were filed.iDisclosures shown as facts. A purchase “cluster” (≥2 members of Congress filing a buy within 90 days) has historically preceded modestly higher forward returns — and it persisted out-of-sample, though it roughly halved after 2021 (see below). A descriptive historical tendency, not a signal to trade and not used in our forecast. See /methodology.
As of 2026-09-16 · point-in-time by filed date
A cluster = ≥2 members of Congress filing a purchase within 90 days. The historical tilt persisted after 2021 but roughly halved (+45 → +32 bp/mo forward 1-month vs the S&P 500 weekly-grid baseline). Descriptive historical tendency — not a signal to trade, and not used in our forecast (audition-log 2026-07-27, recomputed 2026-09-08).
| Member | Chamber | Type | Filed | Traded | Size |
|---|---|---|---|---|---|
| Alan Armstrong | Senate | purchase | 2026-07-21 | 2026-03-27 | $1–15K |
| Ro Khanna | House | sale | 2026-07-06 | 2026-06-02 | $1–15K |
| Ro Khanna | House | sale | 2026-06-09 | 2026-05-01 | $1–15K |
| Ro Khanna | House | sale | 2026-06-09 | 2026-05-15 | $1–15K |
| Ro Khanna | House | purchase | 2026-05-11 | 2026-04-13 | $1–15K |
| Gilbert Cisneros | House | sale | 2026-04-07 | 2026-03-13 | $1–15K |
| Ro Khanna | House | purchase | 2026-04-07 | 2026-03-23 | $1–15K |
| Ro Khanna | House | purchase | 2026-03-09 | 2026-02-24 | $1–15K |
| Gilbert Cisneros | House | purchase | 2026-02-13 | 2026-01-09 | $1–15K |
| Ro Khanna | House | sale | 2026-02-06 | 2026-01-29 | $1–15K |
| Gilbert Cisneros | House | purchase | 2026-01-12 | 2025-12-19 | $1–15K |
| Ro Khanna | House | purchase | 2025-11-06 | 2025-10-07 | $1–15K |
| Ritchie John Torres | House | sale | 2025-08-20 | 2025-07-11 | $1–15K |
| Ro Khanna | House | sale | 2025-08-07 | 2025-07-01 | $1–15K |
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.